eligibility_summary
Adults 18–<80 with R/R CD7+ peripheral T‑cell lymphoma (PTCL‑NOS, ALCL, TFH/AITL), PET‑avid measurable disease, ≥2 prior systemic therapies, adequate counts/organ function, LVEF≥50%, ECOG 0–1, >3‑month survival, DSA MFI<2000, early patients may need stem‑cell collection. Exclude: cutaneous/EATL/MEITL/HSTCL/ENKTCL/CNS lymphoma, CNS involvement, recent therapy, cardiac/neuro disease, active infection/EBV/CMV/HBV/HCV/syphilis/HIV, autoimmune/immunosuppression/GvHD, live vaccine, steroids, pregnant/lactating, recent trial, allergy, investigator judgment.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: CD7-directed CAR-T cell therapy (RD13-02), an autologous, genetically engineered T‑cell product (adoptive cellular gene therapy). Mechanism: patient T cells are modified to express a chimeric antigen receptor that recognizes CD7, triggering CAR signaling to activate cytotoxicity and eliminate CD7-positive malignant T cells, independent of native TCR. Preconditioning: cyclophosphamide (alkylating agent causing DNA crosslinks) and fludarabine (purine analog antimetabolite) for lymphodepletion to support CAR-T expansion/persistence. Targets: CD7 antigen on T cells in relapsed/refractory peripheral T‑cell lymphoma, pathways engaged include CAR-mediated T‑cell activation, cytokine release, and apoptosis/lysis of CD7+ tumor cells. Early phase, single-arm, open-label study at Ruijin Hospital (China).